Kevin Munnelly

Kevin is passionate about innovation in all areas of life sciences, at the product, process and business model levels. He came to Third Rock to lead technology R&D, providing competitive advantages and product engine differentiation for our companies and seed projects. He and his group improve access to novel technologies and services, develop innovative solutions and deploy platforms for both wet lab and data sciences throughout the discovery and development process. Along with his colleagues, he shares an ambition for accelerating treatments for patients in need.

Prior to joining Third Rock, Kevin has spent the last decade creating, advising or leading technology based Life Science start up companies, most recently as Entrepreneur in Residence for Biological Engineering Ventures, LLC, a technology incubator and life science fund. Prior to that, He was President and CEO of Gen9, Inc until its acquisition by Ginkgo Bioworks. Earlier in his career, Kevin served in a number of scientific, technological and business roles at Life Technologies (acquired by Thermo), Millennium Pharmaceuticals (acquired by Takeda Pharmaceuticals) and Applied Biosystems (acquired by Invitrogen).

Outside of TRV, Kevin is an avid supporter of several local charities and enjoys spending time with his family, friends and especially his pets. He is a self-proclaimed SciFi ‘geek’, a Patriots fan and is always up for a vacation at the beach.